Discovery Early Career Researcher Award - Grant ID: DE140100735
Funder
Australian Research Council
Funding Amount
$395,204.00
Summary
Understanding infectious laryngotracheitis virus recombination. This project will study the factors that lead to recombination between strains of infectious laryngotracheitis virus (ILTV) concomitant with increased virulence. In previous studies of ILTV, two new genotypes of virulent field strains were shown to be independent recombinants derived from distinct attenuated ILTV commercial vaccines. These strains became the dominant field viruses responsible for widespread and severe disease outbre ....Understanding infectious laryngotracheitis virus recombination. This project will study the factors that lead to recombination between strains of infectious laryngotracheitis virus (ILTV) concomitant with increased virulence. In previous studies of ILTV, two new genotypes of virulent field strains were shown to be independent recombinants derived from distinct attenuated ILTV commercial vaccines. These strains became the dominant field viruses responsible for widespread and severe disease outbreaks in Australian poultry flocks. This project will enhance understanding of the conditions that led to these deleterious natural recombination events and enable the industry to avoid the emergence of new virulent field strains in the future. Read moreRead less
Molecular approaches to limit herpesvirus recombination. This project aims to generate safer attenuated herpesvirus vaccines for use in veterinary medicine by genetically manipulating the herpesvirus genome to reduce virus recombination. Recombination is recognised as a safety concern for a range of attenuated herpesvirus vaccines. This project is expected to generate viruses that have an impaired capacity to recombine with other viruses. These viruses will then be tested as candidate vaccines f ....Molecular approaches to limit herpesvirus recombination. This project aims to generate safer attenuated herpesvirus vaccines for use in veterinary medicine by genetically manipulating the herpesvirus genome to reduce virus recombination. Recombination is recognised as a safety concern for a range of attenuated herpesvirus vaccines. This project is expected to generate viruses that have an impaired capacity to recombine with other viruses. These viruses will then be tested as candidate vaccines for use in veterinary medicine. This offers a new approach to developing safer veterinary vaccines that will benefit our important animal industries.Read moreRead less